Cargando…

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study

CNS disorders are lagging behind other indications in implementing genotype-dependent treatment algorithms for personalized medicine. This report uses a biophysically realistic computer model of an associative and dorsal motor cortico-striatal-thalamo-cortical loop and a working memory cortical mode...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spiros, Athan, Geerts, Hugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511786/ https://www.ncbi.nlm.nih.gov/pubmed/34658776 http://dx.doi.org/10.3389/fnins.2021.738903

Ejemplares similares

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
por: Spiros, Athan, et al.
Publicado: (2014)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
por: Geerts, Hugo, et al.
Publicado: (2015)

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
por: Geerts, Hugo, et al.
Publicado: (2018)

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
por: Geerts, Hugo, et al.
Publicado: (2020)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development
por: Spiros, Athan, et al.
Publicado: (2012)

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2018)

A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
por: Geerts, H, et al.
Publicado: (2013)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response
por: Geerts, Hugo, et al.
Publicado: (2012)

Prediction of Efficacy of Vabicaserin, a 5-HT(2C) Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model
por: Liu, J, et al.
Publicado: (2014)

A biophysically realistic computer model of Alzheimer pathology to guide the development of symptomatic drugs
por: Roberts, Patrick D, et al.
Publicado: (2012)

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
por: Roberts, Patrick D, et al.
Publicado: (2012)

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease
por: Geerts, Hugo, et al.
Publicado: (2013)

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia
por: Freyberg, Zachary, et al.
Publicado: (2017)

Antipsychotic Effects on Cortical Morphology in Schizophrenia and Bipolar Disorders
por: Feng, Ruiqi, et al.
Publicado: (2020)

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment
por: Ye, Jiaen, et al.
Publicado: (2019)

A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2013)

Microglial intracellular Ca(2+) signaling as a target of antipsychotic actions for the treatment of schizophrenia
por: Mizoguchi, Yoshito, et al.
Publicado: (2014)

Phenotype-Based Genetic Association Studies (PGAS)—Towards Understanding the Contribution of Common Genetic Variants to Schizophrenia Subphenotypes
por: Ehrenreich, Hannelore, et al.
Publicado: (2014)

A commentary on “Antipsychotic-induced Parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders”
por: Salem, Amir, et al.
Publicado: (2015)

Metformin Enhances Antidepressant/Antipsychotic Combination Therapy of Schizophrenia With Comorbid Depression in a Murine Model
por: Zhou, Chunhua, et al.
Publicado: (2020)

A Real-World Observation of Antipsychotic Effects on Brain Volumes and Intrinsic Brain Activity in Schizophrenia
por: Chen, Yifan, et al.
Publicado: (2022)

Identification of VIPR2 rare and common variants in the Chinese Han population with schizophrenia
por: Yin, Jiajun, et al.
Publicado: (2023)

Common Genetic Variant in VIT Is Associated with Human Brain Asymmetry
por: Tadayon, Sayed H., et al.
Publicado: (2016)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Sleep spindle deficits in antipsychotic-naïve early course schizophrenia and in non-psychotic first-degree relatives
por: Manoach, Dara S., et al.
Publicado: (2014)

Response to: A Commentary on “Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders”
por: Potvin, Stéphane, et al.
Publicado: (2015)

The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: A narrative review
por: Zhou, Ruqin, et al.
Publicado: (2022)

Blood Gene Expression Profile Predicts Response to Antipsychotics
por: Sainz, Jesus, et al.
Publicado: (2018)

Common genetic variants contribute to heritability of age at onset of schizophrenia
por: Sada-Fuente, Ester, et al.
Publicado: (2023)

Predictive Biomarkers for Antipsychotic Treatment Response in Early Phase of Schizophrenia: Multi-Omic Measures Linking Subcortical Covariant Network, Transcriptomic Signatures, and Peripheral Epigenetics
por: Zong, Xiaofen, et al.
Publicado: (2022)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia
por: Liang, Wei, et al.
Publicado: (2020)

Common variants in polygenic schizophrenia
por: Glessner, Joseph T, et al.
Publicado: (2009)

A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales
por: Roberts, Rossela, et al.
Publicado: (2018)

Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
por: Geerts, Paul, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_aa9lo0jddaroir5mhuj6nrvqj2